#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Dissecting molecular cross-talk between Nrf2 andNF-κB response pathways"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Esther Wollert"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
# DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET Citation = {"PubMed", "26551702"}

SET Evidence = "Among the most studied Nrf2-target genes are NAD(P)H
dehydrogenase quinone 1 (NQO1), heme oxygenase-1 (HO-
1), γ -glutamyl cysteine ligase modulatory subunit (GCLM),
the catalytic subunit (GCLC) and ferritin, which function
to maintain a reducing environment within the cell [2–4]."
#Nrf2 is NFE2L2
#target as transcription factor
act(p(HGNC:NFE2L2),ma(tscript)) reg r(HGNC:NQO1)
act(p(HGNC:NFE2L2),ma(tscript)) reg r(FPLX:HMOX)
act(p(HGNC:NFE2L2),ma(tscript)) reg r(HGNC:GCLM)
act(p(HGNC:NFE2L2),ma(tscript)) reg r(HGNC:GCLC)
act(p(HGNC:NFE2L2),ma(tscript)) reg r(HGNCGENEFAMILY:"Ferritin subunits")

SET Evidence = "Moreover, Nrf2 also plays a prominent role in
orchestrating glucose metabolism by mediating transcription
of components of the pentose phosphate pathway [7]."
p(HGNC:NFE2L2) -- bp(GO:"glucose metabolic process")
p(HGNC:NFE2L2) reg bp(GO:"pentose-phosphate shunt")

SET Evidence = "The best
characterized mechanism of Nrf2 regulation is mediated
by interaction with the Kelch-like ECH-associated protein
1 (Keap1)–Cullin3–Rbx1 complex, which mediates Nrf2
ubiquitination and subsequent proteasomal degradation [8]."
complex(p(HGNC:KEAP1),p(HGNC:CUL3),p(HGNC:RBX1)) reg p(HGNC:NFE2L2)
complex(p(HGNC:KEAP1),p(HGNC:CUL3),p(HGNC:RBX1)) -> p(HGNC:NFE2L2,pmod(Ub))
p(HGNC:NFE2L2,pmod(Ub)) -> deg(p(HGNC:NFE2L2))
bp(GO:"proteasomal protein catabolic process") -> deg(p(HGNC:NFE2L2))

SET Evidence = " Oxidizing and
electrophilic agents, such as free ROS and plant-derived
phenolic compounds, among many others, can modify these
cysteine residues [9]. This causes a conformational change in
Keap1, preventing subsequent binding of newly synthesized
Nrf2, which promptly accumulates in the nucleus [10]."
a(CHEBI:"reactive oxygen species") -| complex(p(HGNC:KEAP1),p(HGNC:NFE2L2))
a(CHEBI:"phenolic radical") -| complex(p(HGNC:KEAP1),p(HGNC:NFE2L2))
complex(p(HGNC:KEAP1),p(HGNC:NFE2L2)) -| p(HGNC:NFE2L2,loc(MESH:"Cell Nucleus"))

SET Evidence = " There,
Nrf2 associates with small Maf proteins (sMaf) and binds to
antioxidant responsive elements (ARE) in the promoters of
its target genes."
SET MeSHAnatomy = "Cell Nucleus"
p(HGNC:NFE2L2,loc(MESH:"Cell Nucleus")) -> complex(p(FPLX:MAF),p(HGNC:NFE2L2))
p(HGNC:NFE2L2,loc(MESH:"Cell Nucleus")) -> complex(g(MESH:"Antioxidant Response Elements"),p(HGNC:NFE2L2))
UNSET MeSHAnatomy

SET Evidence = "however, Nrf2 can either be
degraded in the nucleus via the β-TrCP–GSK3β axis or
alternatively it may translocate back to the cytoplasm where
it is swiftly degraded by Keap1 [12,13]."
p(HGNC:BTRC) -> deg(p(HGNC:NFE2L2))
p(HGNC:GSK3B) -> deg(p(HGNC:NFE2L2))
tloc(p(HGNC:NFE2L2), fromLoc(MESH:"Cell Nucleus"),toLoc(MESH:Cytosol)) -> deg(p(HGNC:NFE2L2))
SET MeSHAnatomy = "Cytosol"
p(HGNC:KEAP1) -> deg(p(HGNC:NFE2L2))
UNSET MeSHAnatomy

SET Evidence = "The NF-κB complex is a key transcription
factor that mediates immune responses to bacterial and
viral infections, inflammation, aspects of development, cell
proliferation and protection against UV radiation [15]."
p(FPLX:NFkappaB) reg bp(GO:"immune response")
p(FPLX:NFkappaB) reg path(MESH:Inflammation)
p(FPLX:NFkappaB) reg bp(GO:"developmental process")
p(FPLX:NFkappaB) reg bp(GO:"cell population proliferation")
p(FPLX:NFkappaB) reg bp(GO:"UV protection")

SET Evidence = "Pro-
inflammatory cytokines such as tumour necrosis factor
(TNF)α, interleukin (IL)-1β and bacterial lipopolysaccharide
(LPS) are among the most potent NF-κB activators, acting on
the extracellular receptors and initiating a relay of intracellular
phosphorylation events, which co-ordinate signalling and
conditional cell responses [16]."
p(HGNC:TNF) -> act(p(FPLX:NFkappaB))
p(HGNC:IL1B) -> act(p(FPLX:NFkappaB))
a(CHEBI:lipopolysaccharide) -> act(p(FPLX:NFkappaB))

SET Evidence = "Phosphorylation of IκBα, the
negative regulator of NF-κB, prompts an interaction with the
β-TrCP–Skp1–Cullin1 complex driving IκBα ubiqitination
and proteasomal degradation, releasing NF-κB subunits,
which then translocate to the nucleus [17]."
#IkBa is NFKBIA
p(HGNC:NFKBIA) -| act(p(FPLX:NFkappaB))
p(HGNC:NFKBIA, pmod(Ph)) -> complex(p(HGNC:NFKBIA),p(HGNC:CUL1),p(HGNC:BTRC),p(HGNC:SKP1))
complex(p(HGNC:NFKBIA),p(HGNC:CUL1),p(HGNC:BTRC),p(HGNC:SKP1)) -> p(HGNC:NFKBIA, pmod(Ub))
complex(p(HGNC:NFKBIA),p(HGNC:CUL1),p(HGNC:BTRC),p(HGNC:SKP1)) -> deg(p(HGNC:NFKBIA))
deg(p(HGNC:NFKBIA)) -> tloc(p(FPLX:NFkappaB),fromLoc(MESH:Cytosol),toLoc(MESH:"Cell Nucleus"))

SET Evidence = "In order to respond effectively to acute inflammation, NF-
κB also prompts an increase in mitochondrial activity and
NADPH oxidase expression, which are the main sources of
the endogenous free radicals [19,20]."
SET MeSHDisease = "Inflammation"
p(FPLX:NFkappaB) -> act(a(MESH:Mitochondria))
p(FPLX:NFkappaB) -> p(FPLX:"NADPH_oxidase")
act(a(MESH:Mitochondria)) -> a(CHEBI:radical)
p(FPLX:"NADPH_oxidase") -> a(CHEBI:radical)
UNSET MeSHDisease

SET Evidence = "The first insight into the interconnected nature of Nrf2
and NF-κB pathways came from the study of the Nrf2
knockout (KO) mice, which exhibit a neurodegenerative
phenotype."
SET Species = "10090"
p(HGNC:NFE2L2) -| path(MESH:"Neurodegenerative Diseases")
UNSET Species

SET Evidence = " Additionally, in the experimental model of
brain injury the lack of Nrf2 has been associated with
the augmentation of cytokine production [22]."
SET MeSHDisease = "Brain Injuries"
p(HGNC:NFE2L2) pos a(MESH:Cytokines)
UNSET MeSHDisease

SET Evidence = " Moreover,
LPS-treated astrocytic and microglial cultures show more
pronounced NF-κB activity compared with wild-type cells."
SET MeSHAnatomy = {"Astrocytes","Microglia"}
a(CHEBI:lipopolysaccharide) -> act(p(FPLX:NFkappaB))
UNSET MeSHAnatomy

SET Evidence = "The resulting elevation of cytokine production contributes to
astrogliosis, neuronal death and demyelination of neuronal
axons, which is an underlying cause of the neurodegenerative
phenotype of the Nrf2 KO animals [23,24]."
act(p(FPLX:NFkappaB)) -> a(MESH:Cytokines)
SET MeSHAnatomy = "Astrocytes"
a(MESH:Cytokines) -> path(MESH:Gliosis)
UNSET MeSHAnatomy
a(MESH:Cytokines) -> bp(GO:"neuron death")
SET MeSHAnatomy = "Axons"
a(MESH:Cytokines) -| bp(GO:"myelination")
UNSET MeSHAnatomy

SET Evidence = "Also, studies
on Nrf2 − / − MEFs revealed enhanced IKKβ activity, aug-
menting the phosphorylation of IκBα and its subsequent
degradation [25]."
#IKKβ is IKBKB
p(HGNC:NFE2L2) -| act(p(HGNC:IKBKB))
act(p(HGNC:IKBKB)) -> p(HGNC:NFKBIA, pmod(Ph))
p(HGNC:NFKBIA, pmod(Ph)) -> deg(p(HGNC:NFKBIA))

SET Evidence = "There have been numerous studies conducted on Nrf2
activating phytochemicals such as sulforaphane (SFP),
which is abundant in cruciferous vegetables, as well as
synthetic inducers such as 2-cyano-3,12 dioxooleana-
1,9 dien-28-imidazolide (CDDO-Im) and their anti-
inflammatory potential."
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))
a(PUBCHEM:9958995) -> act(p(HGNC:NFE2L2))

SET Evidence = "Pre-stimulation of Nrf2 in primary
peritoneal macrophages dampens the production of COX-2
(cyclooxygenase 2), TNFα, iNOS (inducible nitric oxide
synthase) and IL-1β in response to LPS."
act(p(HGNC:NFE2L2)) -| p(HGNC:PTGS2)
act(p(HGNC:NFE2L2)) -| p(HGNC:TNF)
act(p(HGNC:NFE2L2)) -| p(HGNC:NOS2)

SET Evidence = " What
is more, the increase in Nrf2 activity in lupus nephritis leads
to the accumulation of glutathione (GSH), which effectively
buffers free radicals and prevents the activation of p65,
resulting in reduced deposition of extracellular matrix [28]."
SET MeSHDisease = "Lupus Nephritis"
act(p(HGNC:NFE2L2)) -> a(MESH:Glutathione)
a(MESH:Glutathione) -| a(CHEBI:radical)
a(MESH:Glutathione) -| act(p(HGNC:RELA))
a(MESH:Glutathione) -| deg(a(MESH:"Extracellular Matrix"))
UNSET MeSHDisease

SET Evidence = "Levels of GSH are thought to decrease with age and it is
a likely contributing factor to the exacerbation of diseases
underlined by chronic inflammation [29]."
bp(GO:aging) neg a(MESH:Glutathione)

SET Evidence = "Increases in
HO-1 activity in endothelial cells leads to inhibition of NF-
κB-mediated transcription of adhesion molecules such as E-
Selectin and vascular cell adhesion molecule 1 (VCAM-1),
through the action of bilirubin and possibly by the decrease
in free intracellular iron ions [30]."
SET MeSHAnatomy = "Endothelial Cells"
act(p(FPLX:HMOX)) -| act(p(FPLX:NFkappaB),ma(tscript))
act(p(FPLX:HMOX)) -| p(HGNC:SELE)
act(p(FPLX:HMOX)) -| p(HGNC:VCAM1)

SET Evidence = "The anti-inflammatory role of Nrf2 is well established;
however, it should be noted that NF-κB activity also regulates
Nrf2-mediated ARE expression."
p(HGNC:NFE2L2) reg act(p(FPLX:NFkappaB),ma(tscript))
act(p(FPLX:NFkappaB),ma(tscript)) reg bp(MESH:"Antioxidant Response Elements")

SET Evidence = " Work by Yu et al. [31] has
shown that p65 assists in increasing the abundance of nuclear
Keap1 levels."
p(HGNC:RELA) -> p(HGNC:KEAP1, loc(MESH:"Cell Nucleus"))

SET Evidence = " As the nuclear
envelope does not permit free entry of proteins larger than
40 kDa, Keap1 is thought to enter the nucleus by interactions
with the import facilitating karyopherin alpha 6 (importin
alpha 7) (otherwise known as KPNA6) [32]."
complex(p(HGNC:KEAP1),p(HGNC:KPNA6)) -> tloc(p(HGNC:KEAP1),fromLoc(MESH:Cytosol),toLoc(MESH:"Cell Nucleus"))

SET Evidence = " Consequently,
KPNA6 overexpression results in decreased levels of HO-1
and NQO1. "
p(HGNC:KPNA6) -| p(FPLX:HMOX)
p(HGNC:KPNA6) -| p(HGNC:NQO1)

SET Evidence = "The most well-established mechanism of inhibition of
Nrf2 by p65 activity is a competition of both proteins
for the transcriptional co-activator CBP (CREB-binding
protein)–p300 complex."
act(p(HGNC:RELA)) -| act(p(HGNC:NFE2L2))
act(p(HGNC:RELA)) -| act(complex(p(HGNC:CREBBP),p(HGNC:EP300)))
act(complex(p(HGNC:CREBBP),p(HGNC:EP300))) -> act(p(HGNC:NFE2L2))

SET Evidence = "The CBP–p300 has an intrinsic
histone acetyl transferase activity, which leads to local
acetylation of histones and the loosening of chromatin
structure, exposing DNA for transcriptional apparatus
assembly."
act(complex(p(HGNC:CREBBP),p(HGNC:EP300)),ma(GO:"histone acetyltransferase activity")) -> bp(GO:"histone acetylation")
bp(GO:"histone acetylation") -> bp(GO:"chromatin disassembly")
bp(GO:"chromatin disassembly") -> bp(GO:"mRNA transcription")

SET Evidence = " Aside from its role in histone modifications, it
also acetylates non-histone proteins, with Nrf2 and p65
being well-defined targets [33,34]."
act(complex(p(HGNC:CREBBP),p(HGNC:EP300)),ma(GO:"histone acetyltransferase activity")) -> p(HGNC:NFE2L2,pmod(Ac))
act(complex(p(HGNC:CREBBP),p(HGNC:EP300)),ma(GO:"histone acetyltransferase activity")) -> p(HGNC:RELA,pmod(Ac))

SET Evidence = "On the other hand, CBP also displays preference of binding
to phosphorylated p65 at Ser 276 ."
p(HGNC:NFE2L2,pmod(Ph,Ser,276)) -> complex(p(HGNC:CREBBP),p(HGNC:NFE2L2))

SET Evidence = " Overexpression of p65 is
thought to limit the availability of CBP for Nrf2 complex
formation, prioritizing transcription of the κB driven genes."
p(HGNC:RELA) -| complex(p(HGNC:CREBBP),p(HGNC:NFE2L2))
p(HGNC:RELA) -> act(p(FPLX:NFkappaB),ma(tscript))

SET Evidence = "In addition, p65 can induce repression of transcription by
de-acetylation of histones, through association with histone
deacetylase (HDAC)."
complex(p(HGNC:RELA),p(FPLX:HDAC)) -> bp(GO:"histone deacetylation")

SET Evidence = " Specific cell
types show induction of Nrf2 protein levels and increased
target gene expression in response to TNFα."
p(HGNC:TNF) -> act(p(HGNC:NFE2L2),ma(tscript))

SET Evidence = " RAC1 activation by LPS
can activate Nrf2-mediated HO-1 expression, which in turn
dampens the pro-inflammatory activity of NF-κB."
a(CHEBI:lipopolysaccharide) -> act(p(HGNC:RAC1))
act(p(HGNC:RAC1)) -> act(p(HGNC:NFE2L2),ma(tscript))
act(p(HGNC:NFE2L2),ma(tscript)) -> p(FPLX:HMOX)
p(FPLX:HMOX) -| act(p(FPLX:NFkappaB))
act(p(FPLX:NFkappaB)) -> bp(GO:"inflammatory response")

SET Evidence = " RAC1
can also cause an NF-κB-mediated increase in Nrf2 levels,"
p(HGNC:RAC1) -> p(HGNC:NFE2L2)
act(p(FPLX:NFkappaB)) -> p(HGNC:NFE2L2)

SET Evidence = "Aside from its regulatory role in the Nrf2–ARE pathway,
Keap1 has been found to interact and negatively regulate
IKKβ."
#IKKβ is IKBKB
p(HGNC:KEAP1) -| act(p(HGNC:IKBKB))

SET Evidence = "Keap1 is
thought to prevent HSP90 binding to IKKβ, which triggers
its autophagic degradation."
p(HGNC:KEAP1) -> complex(p(HGNC:IKBKB),p(FPLX:HSP90))
complex(p(HGNC:IKBKB),p(FPLX:HSP90)) -> deg(p(HGNC:IKBKB))

SET Evidence = "Additionally, Keap1 decreases the
phosphorylation of IKKβ possibly by concealing the residues
to which phosphate groups are otherwise attached."
p(HGNC:KEAP1) -| p(HGNC:IKBKB,pmod(Ph))

SET Evidence = "Overall,
the outcome of the Keap1–IKKβ interaction is the negative
regulation of NF-κB though stabilization of IKBα [39]."
#IkBa is NFKBIA
complex(p(HGNC:IKBKB),p(HGNC:KEAP1)) -> p(HGNC:NFKBIA)
complex(p(HGNC:IKBKB),p(HGNC:KEAP1)) -| act(p(FPLX:NFkappaB))

SET Evidence = "Keap1 is thought to deplete Nrf2 from the cytoplasm,
however the F-box protein β-TrCP, a component of the
Skp1–Cullin1–β-TrCP E3 ligase complex, controls nuclear
Nrf2 levels [12,40]. "
p(HGNC:KEAP1) -| p(HGNC:NFE2L2,loc(MESH:Cytosol))
p(HGNC:BTRC) reg p(HGNC:NFE2L2,loc(MESH:Cytosol))

SET Evidence = "The mechanism of degradation via β-
TrCP differs considerably from the Keap1 mode of action as
it only recognizes and binds to phosphorylated substrates."
#substrate mentioned before: Nrf2
p(HGNC:BTRC) -> deg(p(HGNC:NFE2L2,pmod(Ph)))

SET Evidence = "The kinase that phosphorylates and marks Nrf2 for β-TrCP
binding is GSK3β."
p(HGNC:GSK3B) -> p(HGNC:NFE2L2,pmod(Ph))
p(HGNC:NFE2L2,pmod(Ph)) -> complex(p(HGNC:NFE2L2),p(HGNC:BTRC))

SET Evidence = "Interestingly, p65 is also a substrate for
GSK3β phosphorylation, which is thought to modulate p65
DNA binding affinity, but can have both positive and negative
effects on NF-κB depending on the cellular context [41,42]."
p(HGNC:GSK3B) -> p(HGNC:RELA,pmod(Ph))
p(HGNC:RELA,pmod(Ph)) reg complex(p(HGNC:RELA),a(MESH:DNA))

SET Evidence = "The canonical role of β-TrCP is the regulation of IκBα
degradation in response to cytokines [17]."
a(MESH:Cytokines) -> act(p(HGNC:BTRC))
act(p(HGNC:BTRC)) reg deg(p(HGNC:NFKBIA))

SET Evidence = "Therefore, β-TrCP
function can lead to augmentation of NF-κB activity as well
as to inhibition of Nrf2–ARE transcription."
p(HGNC:BTRC) -> act(p(FPLX:NFkappaB))
p(HGNC:BTRC) -| act(p(HGNC:NFE2L2),ma(tscript))

SET Evidence = "Another Nrf2 target gene, p62 is involved in modulation
of antioxidant and inflammatory activities."
#p62 is SQSTM1
act(p(HGNC:NFE2L2),ma(tscript)) -> p(HGNC:SQSTM1)
p(HGNC:SQSTM1) reg bp(GO:"inflammatory response")
p(HGNC:SQSTM1) reg bp(GO:"response to oxidative stress")

SET Evidence = "p62 also acts as
a protein scaffold, enhancing Nrf2 activity by mediating the
autophagosomal degradation of Keap1 [43]."
p(HGNC:SQSTM1) -> act(p(HGNC:NFE2L2))
p(HGNC:SQSTM1) -> deg(p(HGNC:KEAP1))

SET Evidence = "The ability of
p62 to oligomerize, promotes ubiquitination and activation
of TNFα receptor-associated factor 6 (TRAF6), enhancing
nerve growth factor (NGF)-mediated NF-κB signalling [44]."
p(HGNC:SQSTM1) -> p(HGNC:TRAF6, pmod(Ub))
p(HGNC:SQSTM1) -> act(p(HGNC:TRAF6))
act(p(HGNC:TRAF6)) -> act(p(HGNC:NGF))
act(p(HGNC:NGF)) -> act(p(FPLX:NFkappaB))

SET Evidence = "Finally, Nrf2 is thought to act mainly as a dimer with
sMaf proteins, one of them being MafK has been shown to
modulate transcriptional activity of p65."
complex(p(HGNC:NFE2L2),p(HGNC:MAFK)) reg act(p(HGNC:RELA),ma(tscript))

SET Evidence = "MafK is thought to
facilitate the interaction of p65 and CBP, leading to increases
in acetylation of p65 and its overexpression augments
production of cytokines in response to LPS."
p(HGNC:MAFK) -> complex(p(HGNC:CREBBP),p(HGNC:RELA))
complex(p(HGNC:CREBBP),p(HGNC:RELA)) -> p(HGNC:RELA),pmod(Ac))
p(HGNC:MAFK) -> a(MESH:Cytokines)

SET Evidence = " Knockdown
of Nrf2 is associated with increased levels of MafK, therefore
the activity of Nrf2 could be involved in maintaining low
levels of this protein, disallowing excessive p65 acetylation
[45]."
p(HGNC:NFE2L2) -| p(HGNC:MAFK)

SET Evidence = "Several triterpenoids and phytochemical Nrf2-
inducing compounds, such as CDDO-Im and SFP have
shown promising results in reducing inflammation of the
central nervous system (CNS) and importantly are also able
to cross the blood-brain-barrier [24,46,47]. "
a(PUBCHEM:9958995) -> act(p(HGNC:NFE2L2))
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))
SET MeSHAnatomy = "Central Nervous System"
a(PUBCHEM:9958995) -| path(MESH:Inflammation)
a(CHEBI:sulforaphane) -| path(MESH:Inflammation)
UNSET MeSHAnatomy

SET Evidence = "In addition to synthetic compounds that are used in
disease settings, many phytochemicals naturally occurring
in fruit and vegetables such as SFP, cinnamate, resveratrol
or curcumin all have the potential to extenuate chronic
inflammation. These compounds act by activating Nrf2 and
increasing the antioxidant protection of the cells, to alleviate
the damage from ROS [3,24,48]. "
a(CHEBI:sulforaphane) -| path(MESH:Inflammation)
a(CHEBI:cinnamate) -| path(MESH:Inflammation)
a(CHEBI:resveratrol) -| path(MESH:Inflammation)
a(CHEBI:curcumin) -| path(MESH:Inflammation)
a(CHEBI:sulforaphane) -> act(p(HGNC:NFE2L2))
a(CHEBI:cinnamate) -> act(p(HGNC:NFE2L2))
a(CHEBI:resveratrol) -> act(p(HGNC:NFE2L2))
a(CHEBI:curcumin) -> act(p(HGNC:NFE2L2))
a(CHEBI:sulforaphane) -> bp(GO:"response to oxidative stress")
a(CHEBI:cinnamate) -> bp(GO:"response to oxidative stress")
a(CHEBI:resveratrol) -> bp(GO:"response to oxidative stress")
a(CHEBI:curcumin) -> bp(GO:"response to oxidative stress")
